PUBLICATION

Investigations regarding the utility of prodigiosenes to treat leukemia

Authors
Smithen, D.A., Forrester, A.M., Corkery, D.P., Dellaire, G., Colpitts, J., McFarland, S.A., Berman, J.N., and Thompson, A.
ID
ZDB-PUB-121019-37
Date
2013
Source
Organic & biomolecular chemistry   11(1): 62-68 (Journal)
Registered Authors
Berman, Jason, Corkery, Dale, Forrester, Michael
Keywords
none
MeSH Terms
  • Animals
  • Dose-Response Relationship, Drug
  • Pyrroles/chemical synthesis
  • Pyrroles/chemistry
  • Pyrroles/pharmacology*
  • Molecular Structure
  • Humans
  • Disease Models, Animal
  • Antineoplastic Agents/chemical synthesis
  • Antineoplastic Agents/chemistry
  • Antineoplastic Agents/pharmacology*
  • Cell Line, Tumor
  • Zebrafish
  • Cell Proliferation/drug effects
  • Neoplasms, Experimental/drug therapy*
  • Neoplasms, Experimental/pathology
  • Prodigiosin/analogs & derivatives
  • Prodigiosin/chemistry
  • Prodigiosin/pharmacology*
  • Structure-Activity Relationship
  • Leukemia/drug therapy*
  • Leukemia/pathology
(all 22)
PubMed
23070266 Full text @ Org. Biomol. Chem.
Abstract

Prodigiosenes, possessing a 4-methoxypyrrolyldipyrrin skeleton, are known for their anti-cancer activity. Structural modification of the C-ring resulted in a series of prodigiosenes that displayed promising activity against leukemia cell lines during in vitro analysis against the NCI 60 cancer cell line panel. Further in vivo studies of these compounds using the zebrafish model showed persistence of anti-leukemia properties in human K562 chronic myelogenous leukemia cells.

Genes / Markers
Figures
No images available
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Antibodies
Orthology
Engineered Foreign Genes
Mapping